Back to News Items

August 2012: New article: Tofacitinib is a Viable Treatment for Ulcerative Colitis

* Currently in late-stage clinical trials for the treatment of ulcerative colitis, Tofacitinib was initially expected to gain FDA 

  approval on August 21, 2012 for its use in treating rheumatoid arthritis.

* Analysts are predicting that annual  sales of Tofacitinib could eventually exceed $2 billion.

* Ulcerative colitis is a devastating, chronic disease that causes inflammation and sores, called ulcers, in the inner lining of

  the large intestine, including the colon and the rectum.

* Ulcerative colitis affects roughly 700,000 Americans.

* Tofacitinib is an oral option for the treatment of ulcerative colitis, which is easier for administration when compared to

  current comparable injectable treatments.


Dun and Bradstreet